Key facts
- This page summarizes Nerissa Kreher's Form 4 filing for Entrada Therapeutics, Inc. (TRDA).
- 5 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 06 Sep 2023, 17:08.
Nerissa Kreher - 01 Sep 2023 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- TRDA
- Reported as of
- 01 Sep 2023
- Net transaction value
- -$17,821
- SEC form
- 4
- Accepted by SEC
- 06 Sep 2023, 17:08:54 UTC
- Prior SEC filing
- 04 Aug 2023
- Next SEC filing
- 25 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jared Cohen, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Nerissa Kreher filed Form 4 for Entrada Therapeutics, Inc. (TRDA) on 06 Sep 2023.
Change
- Previous filing in this sequence was filed on 04 Aug 2023.
- Current net transaction value: -$17,821.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TRDA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +14,200
- Change %
- +52%
- Price
- $0.000000
- Shares after
- 41,330
- Date
- 01 Sep 2023
- Ownership
- Direct
- Footnotes
- F1
TRDA
transaction
Common Stock
Tax liability
- Transaction value
- $5,799
- Shares
- -401
- Change %
- -0.97%
- Price
- $14.46
- Shares after
- 40,929
- Date
- 05 Sep 2023
- Ownership
- Direct
- Footnotes
- F2
TRDA
transaction
Common Stock
Sale
- Transaction value
- $11,728
- Shares
- -871
- Change %
- -2.1%
- Price
- $13.46
- Shares after
- 40,058
- Date
- 06 Sep 2023
- Ownership
- Direct
- Footnotes
- F3, F4
TRDA
transaction
Common Stock
Sale
- Transaction value
- $294
- Shares
- -21
- Change %
- -0.05%
- Price
- $14.00
- Shares after
- 40,037
- Date
- 06 Sep 2023
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TRDA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +21,500
- Change %
- Price
- $0.000000
- Shares after
- 21,500
- Date
- 01 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 21,500
- Exercise price
- $15.41
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 5 footnotes
Footnote F1
Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2024; (ii) 25% on September 1, 2025; (iii) 25% on September 1, 2026 and (iv) the remaining 25% on September 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.
Footnote F2
This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.
Footnote F3
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F5
25% of the option shares shall vest and become exercisable on September 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on September 1, 2027.